Myxoid solitary fibrous tumour of the meninges: case report

M. Kösem,M. Arslan,Olgun Kontaş,Ö. Ünal
DOI: https://doi.org/10.1111/j.1365-2559.2006.02499.x
2006-10-01
Histopathology
Abstract:n 1⁄4 33; Figure 2C). Taking the data together, AP-2 was strongly expressed in human Schwann cell-derived tumours correlating positively with malignancy. Comparable results have been shown for human breast carcinoma cell lines. Therefore, AP-2 could activate oncogenes. Alternatively, increased AP-2 expression may reflect an undifferentiated state of neoplastic Schwann cells similar to the state of embryonic precursor Schwann cells, which also show AP-2 expression. In addition, we observed that AP-2 expression significantly increased with cell density, being lowest in neurofibromas and highest in MPNST. Nearly 100% of cells expressed AP-2 in MPNST, independent of total cellular density. We deduce that AP-2 expression increases with malignancy in Schwann cell-derived tumours. This contrasts with other studies which have demonstrated that AP-2 inhibits tumour growth. Therefore, our data do not support the hypothesis that AP-2 is a tumour suppressor in nerve sheath tumours. Furthermore, we observed slight AP-2 expression in 9 ⁄ 15 human peripheral nerve biopsies. AP-2 is known to be a regulator of Schwann cell development. AP-2a and AP-2c mRNA and proteins are expressed by precursor Schwann cells during embryonic development of sciatic nerves and both genes are strongly down-regulated as precursors mature into Schwann cells. However, our observations contradict the hypothesis that AP-2 expression is absent in mature Schwann cells. Thus, AP-2 might have unknown functions in the peripheral nervous system following embryonic Schwann cell maturation.
What problem does this paper attempt to address?